Parasvi Sumantrai Patel, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| BRCA1 Protein | 5 | 2023 | 1155 | 1.720 |
Why?
|
| BRCA2 Protein | 4 | 2023 | 802 | 1.110 |
Why?
|
| Genomic Instability | 5 | 2024 | 715 | 0.930 |
Why?
|
| DNA Replication | 5 | 2024 | 1428 | 0.840 |
Why?
|
| DNA Topoisomerases | 1 | 2022 | 4 | 0.800 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2021 | 122 | 0.680 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 1748 | 0.500 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2023 | 1901 | 0.400 |
Why?
|
| Transcription, Genetic | 1 | 2023 | 7599 | 0.320 |
Why?
|
| Ovarian Neoplasms | 2 | 2021 | 4907 | 0.280 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2024 | 35 | 0.230 |
Why?
|
| Uracil | 1 | 2024 | 210 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2024 | 211 | 0.200 |
Why?
|
| Cytosine | 1 | 2023 | 213 | 0.200 |
Why?
|
| Hexokinase | 1 | 2022 | 124 | 0.190 |
Why?
|
| DNA Mismatch Repair | 1 | 2023 | 433 | 0.170 |
Why?
|
| Methyltransferases | 1 | 2023 | 373 | 0.170 |
Why?
|
| DNA | 5 | 2024 | 7211 | 0.160 |
Why?
|
| RNA Polymerase II | 1 | 2023 | 547 | 0.160 |
Why?
|
| Mutation | 1 | 2023 | 30228 | 0.150 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2018 | 85 | 0.150 |
Why?
|
| DNA Repair | 2 | 2024 | 2048 | 0.150 |
Why?
|
| Nucleosides | 1 | 2018 | 131 | 0.150 |
Why?
|
| Cell Death | 1 | 2023 | 1682 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 3620 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2023 | 5801 | 0.100 |
Why?
|
| DNA, Single-Stranded | 2 | 2024 | 351 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2021 | 2630 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3617 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4646 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 9614 | 0.080 |
Why?
|
| Proteins | 1 | 2024 | 6006 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2018 | 1980 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14481 | 0.060 |
Why?
|
| Animals | 6 | 2024 | 169337 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 21162 | 0.060 |
Why?
|
| Mice | 5 | 2024 | 82017 | 0.060 |
Why?
|
| Alu Elements | 1 | 2024 | 116 | 0.060 |
Why?
|
| DNA Damage | 2 | 2024 | 2458 | 0.060 |
Why?
|
| Molecular Mimicry | 1 | 2024 | 213 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2023 | 88 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2024 | 293 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 242 | 0.050 |
Why?
|
| Apoptosis | 1 | 2018 | 9516 | 0.050 |
Why?
|
| Humans | 10 | 2024 | 768393 | 0.050 |
Why?
|
| Cytidine Deaminase | 1 | 2024 | 243 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 1009 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2023 | 608 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 17135 | 0.040 |
Why?
|
| Sulfides | 1 | 2018 | 171 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13697 | 0.030 |
Why?
|
| Female | 3 | 2023 | 397089 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2726 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2632 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 6132 | 0.020 |
Why?
|
| Chromatin | 1 | 2022 | 2968 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 3407 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 8634 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 2021 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2024 | 7880 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 4738 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2018 | 3048 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9433 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10478 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2024 | 23631 | 0.010 |
Why?
|
| Neoplasms | 1 | 2024 | 22385 | 0.010 |
Why?
|